Red Light Holland (TRIP) Q2 2026 earnings summary

Executive summary

• Focused on disciplined prioritization and execution across business lines amid industry challenges and macroeconomic volatility.

• Advanced R&D partnerships, including with Irvine Labs and Arizona State University, to develop psilocybin products and microdosing capsules for therapeutic markets.

• Expanded retail presence with Albertsons and launched new functional mushroom gummies in Canada and on Amazon.

• Initiated a Bitcoin strategy to enhance financial infrastructure and flexibility.

Financial highlights

• Total cash balance at $10.226M as of September 30, 2025, down from $11.454M at June 30, 2025.

• Revenue for Q2 2026 was $0.754M, a 44.9% decrease year-over-year from $1.368M in Q2 2025.

• Gross profit for Q2 2026 was $0.327M, down 68.68% from $0.552M in Q2 2025.

• Adjusted EBITDA loss for Q2 2026 was $0.785M, up 61.9% from $0.485M in Q2 2025.

• Total assets stood at $19.018M as of September 30, 2025.

Outlook and guidance

• Anticipates sales rebound for Happy Caps during the holiday season following expanded Albertsons partnership.

• Prioritizing R&D initiatives in psilocybin to drive long-term value and growth.

• Ongoing evaluation of M&A opportunities, especially in research-driven businesses.

• Management remains optimistic, citing a strong cash position and diversified foundation.